<DOC>
	<DOCNO>NCT00694837</DOCNO>
	<brief_summary>The objective trial : To assess safety , tolerability activity nelfinavir give neo-adjuvant concomitant chemoradiotherapy temozolomide patient newly diagnose glioblastoma multiforme . To describe possible effect nelfinavir functional imaging To describe activity nelfinavir vivo block AKT pathway .</brief_summary>
	<brief_title>Study With Nelfinavir Combined Radiochemotherapy Glioblastoma</brief_title>
	<detailed_description>Glioblastoma multiforme malignant common , 50 % , variant primary brain tumour . The treatment strategies disease change appreciably many year consist surgical intervention ( biopsy tumour resection ) post-operative local radiotherapy several year ago . Combined chemoradiotherapy temozolomide moment standard medical practice result joint EORTC-NCIC phase III study randomize radiotherapy alone combine chemoradiotherapy temozolomide show significant improvement 2-years survival 8 % 24 % combine treatment arm ( Stupp 2005 ) . Given poor prognosis patient still poor treatment response , therapeutic improvement remain challenge topic future . The next step improve survival patient group would addition biological modifying and/or antiangiogenic therapy . These strategy motivate fact glioblastoma often express high level vascular endothelial growth factor key mediator blood vessel growth high expression EGFR , upregulates downstream PI3K-AKTpathway . ( Fischer I , Carmeliet P , Koul D ) One possible candidate nelfinavir , protease inhibitor interfere Akt activity downstream EGFR upstream VEGF . ( Geng L , Gorski D , HLu B )</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Histologically confirm glioblastoma multiforme primary diagnosis Tumours enhance preoperative image Age &gt; =1865 year WHO performance status 02 , RTOG RPA class IIIIV . No recent ( &lt; 3 month ) severe cardiac disease ( arrhythmia , congestive heart failure , infarction ) Patient able tolerate full course radiotherapy No previous radiotherapy head neck area . Prior neurosurgery within 6 week treatment No previous irradiation brain . No previous chemotherapy No prior concurrent medical condition would make treatment difficult complete . Medication steroid allow . No use terfenadine , astemizol , cisapride , sildenafil , lovastatin simvastatin concurrent medication metabolize CYP3A4 isoenzyme replace equivalent medication period study : antiarrhythmic ( amiodarone , quinidine ) , neuroleptic ( pimozide ) , sedative/hypnotic agent ( midazolam , triazolam ) , ergot derivative ( dihydroergotamine , ergonovine , ergotamine , methylergonovine ) , HMGCoA reductase inhibitor ( atorvastatin ) , rifampin , rifabutin , felodipine , nifedipine , sildenafil St. John 's wort . Adequate haematological , renal hepatic function No uncontrolled infectious disease , absence know HIV infection , chronic hepatitis B hepatitis C infection Absence medical condition , could interfere oral medication intake ( e.g. , frequent vomiting , partial bowel obstruction ) All patient reproductive potential ( male female ) must use effective contraception whole duration treatment 6 month thereafter . Females must pregnant lactate Willing able comply study prescription Written inform consent patient registration The opposite</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>glioblastoma</keyword>
	<keyword>nelfinavir</keyword>
	<keyword>functional imaging</keyword>
	<keyword>AKT pathway</keyword>
</DOC>